-
公开(公告)号：US12208034B2
公开(公告)日：2025-01-28
申请号：US17303857
申请日：2021-06-09
Applicant: DOSE Medical Corporation
Inventor： David S. Haffner , Thomas W. Burns , Harold A. Heitzmann , Kenneth M. Curry
Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
-
公开(公告)号：US20200375889A1
公开(公告)日：2020-12-03
申请号：US16888384
申请日：2020-05-29
Applicant: Dose Medical Corporation
Inventor： Patrick Michael Hughes , James Shiah , Jack Xie , Jia-Ying Yang
IPC: A61K9/00 , A61K31/4439 , A61K47/34
Abstract: The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.
-
公开(公告)号：US20180333296A1
公开(公告)日：2018-11-22
申请号：US15756906
申请日：2016-09-01
Applicant: DOSE MEDICAL CORPORATION
Inventor： Harold A. Heitzmann , Thomas W. Burns , David S. Haffner
CPC classification number: A61F9/0017 , A61F9/00781 , A61F2250/0001 , A61F2250/0068 , A61K9/0051 , A61K41/0028
Abstract: Disclosed herein are drug delivery implants configured to be implanted into the eye of a subject and serve as intraocular drug depots. The implants reside in an intraocular target site until activation, at which time the implants release the drug (or drugs) housed within the implant in a controlled release fashion.
-
公开(公告)号：US20170135857A1
公开(公告)日：2017-05-18
申请号：US15422384
申请日：2017-02-01
Applicant: Dose Medical Corporation
Inventor： David S. Haffner , Kenneth M. Curry , Harold A. Heitzmann , David Applegate
CPC classification number: A61F9/0017 , A61F9/00781 , A61F2210/0004 , A61F2250/0068 , A61K9/0051
Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
-
公开(公告)号：US20140012177A1
公开(公告)日：2014-01-09
申请号：US13716763
申请日：2012-12-17
Applicant: DOSE MEDICAL CORPORATION
Inventor： Hosheng Tu , Barbara A. Niksch , David S Haffner , Gregory T Smedley , Olav B. Bergheim , Morteza Gharib
IPC: A61F9/007
CPC classification number: A61F9/00781 , A61F9/0017 , A61F2250/0067 , A61L27/54 , A61L2300/258 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L2300/42 , A61L2430/16 , A61M27/002
Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
Abstract translation: 提供了用于治疗眼部疾病的植入物和方法。 一种方法是将植入物引入眼睛的前房。 将植入物植入邻近前房的眼组织中，使植入物的近端位于植入后的前房。 治疗剂从植入物中洗脱到眼睛中。 理想地，治疗剂从植入物的释放受到控制。 治疗剂的受控释放可以是选择的速率和/或选择的持续时间，其可以是情景性的或周期性的。 治疗剂可以是抗增生剂，抗炎药或治疗青光眼或高眼压症的化合物。
-
Patent Agency Ranking
公开(公告)号：US12201557B2
公开(公告)日：2025-01-21
申请号：US18060126
申请日：2022-11-30
Applicant: Dose Medical Corporation
Inventor： David S. Haffner , Kenneth M. Curry , Harold A. Heitzmann , David Applegate
Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
-
公开(公告)号：US12201555B2
公开(公告)日：2025-01-21
申请号：US17219102
申请日：2021-03-31
Applicant: Dose Medical Corporation
Inventor： David S. Haffner , Kenneth M. Curry , Harold A. Heitzmann , David Applegate
Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
-
公开(公告)号：US20240065887A1
公开(公告)日：2024-02-29
申请号：US18452370
申请日：2023-08-18
Applicant: DOSE MEDICAL CORPORATION
Inventor： Harold A. Heitzmann , Thomas W. Burns , David S. Haffner
CPC classification number: A61F9/0017 , A61F9/00781 , A61K9/0051 , A61K41/0028 , A61F2250/0001 , A61F2250/0068
Abstract: Disclosed herein are drug delivery implants configured to be implanted into the eye of a subject and serve as intraocular drug depots. The implants reside in an intraocular target site until activation, at which time the implants release the drug (or drugs) housed within the implant in a controlled release fashion.
-
公开(公告)号：US11883525B2
公开(公告)日：2024-01-30
申请号：US16888384
申请日：2020-05-29
Applicant: Dose Medical Corporation
Inventor： Patrick Michael Hughes , James Shiah , Jack Xie , Jia-Ying Yang
IPC: A61K9/00 , A61K47/34 , A61K31/4439
CPC classification number: A61K9/0019 , A61K9/0051 , A61K31/4439 , A61K47/34
Abstract: The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.
-
公开(公告)号：US11426306B2
公开(公告)日：2022-08-30
申请号：US16277858
申请日：2019-02-15
Applicant: Dose Medical Corporation
Inventor： David S. Haffner , Thomas W. Burns , Harold A. Heitzmann , Kenneth M. Curry
Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.022 seconds)
